Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 15/20 | 0.58 |
| ▸ | NOS2 | P35228 | 14/20 | 0.58 |
| ▸ | NOS3 | P29474 | 12/20 | 0.56 |
| ▸ | PNMT | P11086 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12641204 | 0.83 | NOS1 (0.61) | NOS1NOS2NOS3LOXL2 | |
| SCHEMBL24422635 | 0.82 | NOS1 (0.62) | NOS1NOS2NOS3PNMTENPP2 | |
| SCHEMBL8440754 | 0.78 | TSHR (0.46) | NOS1NOS2NOS3PNMT | |
| SCHEMBL14028969 | 0.78 | NOS1 (0.36) | NOS1NOS2NOS3 | |
| SCHEMBL13715502 | 0.78 | NOS1 (0.41) | NOS1NOS2NOS3 | |
| SCHEMBL11982706 | 0.78 | SIGMAR1 (0.47) | NOS1NOS2 | |
| SCHEMBL1157243 | 0.78 | NOS1 (0.53) | NOS1NOS2NOS3ENPP2 | |
| SCHEMBL8439706 | 0.78 | TRPA1 (0.42) | NOS1NOS2NOS3 | |
| SCHEMBL24423149 | 0.78 | NOS1 (0.58) | NOS1NOS2NOS3PNMTENPP2 | |
| SCHEMBL27278789 | 0.78 | NOS1 (0.53) | NOS1NOS2NOS3PNMTENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-8168656-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2012-05-01 | — | — | US | disclosed |
| US-8084646-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY | 2009-05-07 | — | — | US | disclosed |
| US-7491744-B2 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | VANDERBILT UNIVERSITY (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | NOS1 3165/4885NOS2 3398/4885NOS3 3015/4885 |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | NOS1 2387/4885NOS2 3254/4885NOS3 3624/4885 |
| US-20090118290-A1 | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity | AANAT, FABP2, SI | NOS1 1020/4885NOS2 864/4885NOS3 806/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | NOS1 1803/4885NOS2 1810/4885NOS3 2401/4885 |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | NOS1 2387/4885NOS2 3254/4885NOS3 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.